OBJECTIVE: The ability of human cells to repopulate the bone marrow of nonobese diabetic immunodeficient mice (NOD/SCID) is commonly used as a standard assay to quantify the primitive human hematopoietic stem cell population. We studied the applicability of the immunodeficient RAG2(-/-)gammac(-/-) double-knockout mouse for this purpose. METHODS: RAG2(-/-)gammac(-/-) mice and NOD/SCID mice were injected intravenously (i.v.) with umbilical cord blood-derived CD34(+) cells and engraftment was quantified by determining the human CD45+ cell chimerism in bone marrow at several time points. RAG2(-/-)gammac(-/-) were pretreated with total-body irradiation and depleted of macrophages in liver, spleen, and bone marrow by i.v. injection of clodronate diphosphonate containing liposomes. RESULTS: We demonstrated that the frequency of chimerism and the level of engraftment in macrophage-depleted RAG2(-/-)gammac(-/-) largely resemble that in NOD/SCID mice. Also similar is the multilineage differentiation pattern in the two mouse strains at 7 weeks after transplantation, with a prominent outgrowth in RAG2(-/-)gammac(-/-) of CD19+ cells (88% +/- 10%). Cells of other lineages were clearly less frequent: 9% +/- 2% myeloid cells and 0.1% +/- 0.1% erythroid cells. As for immature progenitors, 6% +/- 1% of the human cells express the CD34 antigen and 0.4% +/- 0.1% have the CD34+,CD33,38,71(-) phenotype. The presence of human committed progenitors (i.e., CFU-GM/BFU-E) was evident. The persistence of human cells at 4 months after transplantation shows that the RAG2(-/-)gammac(-/-) support long-term maintenance of human hematopoiesis. CONCLUSION: Our findings indicate that macrophage-depleted RAG2(-/-)gammac(-/-) are a suitable model for studying human hematopoiesis including multipotential stem cells, and long-term repopulation.
OBJECTIVE: The ability of human cells to repopulate the bone marrow of nonobese diabetic immunodeficientmice (NOD/SCID) is commonly used as a standard assay to quantify the primitive human hematopoietic stem cell population. We studied the applicability of the immunodeficientRAG2(-/-)gammac(-/-) double-knockout mouse for this purpose. METHODS:RAG2(-/-)gammac(-/-) mice and NOD/SCIDmice were injected intravenously (i.v.) with umbilical cord blood-derived CD34(+) cells and engraftment was quantified by determining the humanCD45+ cell chimerism in bone marrow at several time points. RAG2(-/-)gammac(-/-) were pretreated with total-body irradiation and depleted of macrophages in liver, spleen, and bone marrow by i.v. injection of clodronate diphosphonate containing liposomes. RESULTS: We demonstrated that the frequency of chimerism and the level of engraftment in macrophage-depleted RAG2(-/-)gammac(-/-) largely resemble that in NOD/SCIDmice. Also similar is the multilineage differentiation pattern in the two mouse strains at 7 weeks after transplantation, with a prominent outgrowth in RAG2(-/-)gammac(-/-) of CD19+ cells (88% +/- 10%). Cells of other lineages were clearly less frequent: 9% +/- 2% myeloid cells and 0.1% +/- 0.1% erythroid cells. As for immature progenitors, 6% +/- 1% of the human cells express the CD34 antigen and 0.4% +/- 0.1% have the CD34+,CD33,38,71(-) phenotype. The presence of human committed progenitors (i.e., CFU-GM/BFU-E) was evident. The persistence of human cells at 4 months after transplantation shows that the RAG2(-/-)gammac(-/-) support long-term maintenance of humanhematopoiesis. CONCLUSION: Our findings indicate that macrophage-depleted RAG2(-/-)gammac(-/-) are a suitable model for studying humanhematopoiesis including multipotential stem cells, and long-term repopulation.
Authors: Frida Holm; Eva Hellqvist; Cayla N Mason; Shawn A Ali; Nathaniel Delos-Santos; Christian L Barrett; Hye-Jung Chun; Mark D Minden; Richard A Moore; Marco A Marra; Valeria Runza; Kelly A Frazer; Anil Sadarangani; Catriona H M Jamieson Journal: Proc Natl Acad Sci U S A Date: 2015-11-30 Impact factor: 11.205
Authors: Santhi Gorantla; Hannah Sneller; Lisa Walters; John G Sharp; Samuel J Pirruccello; John T West; Charles Wood; Stephen Dewhurst; Howard E Gendelman; Larisa Poluektova Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: Anthony Rongvaux; Tim Willinger; Hitoshi Takizawa; Chozhavendan Rathinam; Wojtek Auerbach; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Elizabeth E Eynon; Sean Stevens; Markus G Manz; Richard A Flavell Journal: Proc Natl Acad Sci U S A Date: 2011-01-24 Impact factor: 11.205
Authors: Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl Journal: Clin Exp Metastasis Date: 2014-04-09 Impact factor: 5.150
Authors: Tom van Meerten; Henk Rozemuller; Samantha Hol; Petra Moerer; Mieke Zwart; Anton Hagenbeek; Wendy J M Mackus; Paul W H I Parren; Jan G J van de Winkel; Saskia B Ebeling; Anton C Martens Journal: Haematologica Date: 2010-09-17 Impact factor: 9.941
Authors: Till Strowig; Anthony Rongvaux; Chozhavendan Rathinam; Hitoshi Takizawa; Chiara Borsotti; William Philbrick; Elizabeth E Eynon; Markus G Manz; Richard A Flavell Journal: Proc Natl Acad Sci U S A Date: 2011-07-25 Impact factor: 11.205
Authors: Michael A Brehm; Amy Cuthbert; Chaoxing Yang; David M Miller; Philip DiIorio; Joseph Laning; Lisa Burzenski; Bruce Gott; Oded Foreman; Anoop Kavirayani; Mary Herlihy; Aldo A Rossini; Leonard D Shultz; Dale L Greiner Journal: Clin Immunol Date: 2010-01-21 Impact factor: 3.969
Authors: Andrei A Postnov; Henk Rozemuller; Viviene Verwey; Henk Lokhorst; Nora De Clerck; Anton C Martens Journal: Calcif Tissue Int Date: 2009-10-09 Impact factor: 4.333